Assessing Long-Term Data With CDK4/6 Inhibitors

This segment focuses on the growing body of long-term clinical data that demonstrates ongoing benefit with CDK4/6 inhibitors in metastatic breast cancer. Extension studies have shown durable progression-free survival, manageable adverse effects, and no emergence of unexpected late toxicities. Panelists note that real-world experiences mirror clinical trial findings, reinforcing the drugs’ role as foundational agents in hormone receptor–positive disease.

Safety over extended use remains a recurring theme. Participants describe how regular laboratory surveillance and dose modification allow continued treatment without compromising efficacy. Importantly, they observe that proactive toxicity management has reduced discontinuation rates over time, further validating the tolerability of these agents in long-term use.

The discussion concludes with optimism about the future of CDK4/6 inhibitors as long-term disease control tools. With continued evidence generation, clinicians are becoming more confident in maintaining therapy for stable patients while exploring ways to integrate these agents across earlier disease settings.